Femoral Artery Closure Devices Market Size, Share, Growth, and Industry Analysis, By Type (5F,6F,7F,8F,Others), By Application (Hospital,Clinic), Regional Insights and Forecast to 2035

Femoral Artery Closure Devices Market Overview

Global Femoral Artery Closure Devices Market size is estimated at USD 1380.32 million in 2026 and is expected to reach USD 2673.38 million by 2035 at a 7.7% CAGR.

The femoral artery closure devices market is expanding due to the increasing volume of catheterization procedures, which exceeded 14 million annually worldwide in 2024, with over 9 million involving femoral access. These devices reduce hemostasis time from 30 minutes to less than 5 minutes and lower complication rates by 22%. The adoption rate in interventional cardiology procedures reached 68% in 2023, compared to 54% in 2020. Technological advancements have led to device deployment success rates above 96%. The global patient pool requiring vascular closure increased by 18% between 2021 and 2024, with over 3.5 million angiography procedures utilizing closure devices annually.

In the United States, over 4.2 million cardiac catheterization procedures were recorded in 2024, with approximately 2.6 million involving femoral artery access. Closure device utilization reached 72% penetration in hospitals, compared to 61% in 2021. The incidence of vascular complications dropped from 6.3% to 3.8% with closure device use. More than 1,500 hospitals across the country adopted advanced collagen-based closure systems, and outpatient procedures increased by 27% between 2022 and 2024. The average time to ambulation decreased from 6 hours to 2 hours in 78% of cases using closure devices, significantly improving patient throughput.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: 78% rise in minimally invasive procedures, 65% increase in catheterization demand, 52% improvement in patient recovery rates, 48% reduction in hospital stays, 71% adoption rate in cardiology departments
• Major Market Restraint: 34% complication concerns, 29% device failure risk, 41% cost sensitivity among hospitals, 26% preference for manual compression, 38% training limitations among clinicians
• Emerging Trends: 67% shift toward bioabsorbable devices, 58% integration of suture-mediated systems, 49% rise in outpatient procedures, 61% demand for rapid hemostasis, 53% adoption of next-generation polymers
• Regional Leadership: 42% North America dominance, 29% Europe contribution, 21% Asia-Pacific growth, 5% Middle East share, 3% Africa expansion
• Competitive Landscape: 36% market share held by top 2 players, 24% share among mid-tier companies, 18% share by emerging manufacturers, 22% fragmented competitive presence
• Market Segmentation: 31% share for 6F devices, 26% for 5F devices, 19% for 7F devices, 14% for 8F devices, 10% others
• Recent Development: 63% increase in product approvals, 47% rise in clinical trials, 39% enhancement in device efficiency, 28% expansion in manufacturing units, 51% innovation in materials

Femoral Artery Closure Devices Market Latest Trends

The femoral artery closure devices market is witnessing significant transformation driven by innovations and clinical adoption patterns. Bioabsorbable closure devices accounted for 46% of newly launched products in 2024, compared to 28% in 2021. Suture-mediated systems captured 39% of procedural usage, while collagen plug-based devices maintained 44% share. Deployment success rates improved to 97% in advanced devices, compared to 91% in earlier models. Outpatient catheterization procedures increased by 33% globally, influencing demand for faster closure solutions.

Technological advancements have reduced complication rates by 19%, while device failure rates dropped to 2.7% in 2024 from 4.1% in 2020. Hospitals adopting automated closure systems increased by 37% between 2022 and 2025. Additionally, over 62% of interventional cardiologists prefer closure devices due to reduced patient recovery time. Training programs for device usage increased by 41%, improving procedural efficiency. The integration of imaging-guided deployment systems rose by 36%, enhancing accuracy and safety.

Femoral Artery Closure Devices Market Dynamics

DRIVER

"Rising demand for minimally invasive cardiovascular procedures."

The global increase in cardiovascular diseases, affecting over 523 million individuals, has driven procedural volumes upward. More than 18 million deaths annually are linked to cardiovascular conditions, leading to increased angiography and angioplasty procedures. Femoral artery access remains dominant in 57% of complex interventions, supporting closure device demand. The reduction in hospital stays by 45% and improved patient turnover rates by 38% further boost adoption. Additionally, over 69% of healthcare providers prioritize faster hemostasis, increasing device usage across hospitals and clinics globally.

RESTRAINT

"Concerns regarding device-related complications and cost."

Despite advancements, complication rates remain at approximately 3.8% in some procedures, with hematoma incidence at 2.1%. Device malfunctions occur in 2.5% of cases, impacting clinician confidence. The cost of closure devices is 2.3 times higher than manual compression methods, limiting adoption in cost-sensitive regions. Around 43% of healthcare facilities in developing regions prefer traditional methods due to budget constraints. Additionally, training requirements for proper device usage affect 36% of institutions, slowing widespread implementation.

OPPORTUNITY

"Expansion in emerging healthcare markets and outpatient care."

Emerging economies reported a 28% increase in catheterization labs between 2021 and 2024, creating new growth avenues. Outpatient procedures grew by 31%, with closure devices used in 66% of cases for rapid discharge. Government investments in healthcare infrastructure increased by 22%, supporting advanced device adoption. Additionally, technological innovations such as bioabsorbable materials saw a 54% increase in demand, providing manufacturers with opportunities to expand product portfolios and enter new markets.

CHALLENGE

"Regulatory complexities and clinical variability."

Regulatory approval timelines average 18 months, delaying product launches. Compliance requirements increased by 27% across major markets, impacting manufacturing timelines. Clinical variability in patient anatomy affects device success rates by up to 6%. Additionally, physician preference varies, with 32% still relying on manual compression techniques. Supply chain disruptions affected 19% of manufacturers in 2023, further challenging market expansion and product availability.

Femoral Artery Closure Devices Market Segmentation

Download FREE Sample to learn more about this report.

By Type

5F: 5F devices accounted for 26% of total usage in 2024, with over 2.1 million procedures utilizing this category. These devices are commonly used in diagnostic angiography, which represents 48% of catheter-based procedures. The average deployment success rate for 5F devices is 95%, with complication rates below 3%. Adoption increased by 17% between 2022 and 2024 due to their compatibility with smaller vessel sizes. Hospitals reported a 21% reduction in post-procedure bleeding using 5F closure systems. Additionally, hemostasis time was reduced to under 6 minutes in 79% of procedures. Patient ambulation within 3 hours was achieved in 68% of cases. Usage in outpatient diagnostic centers increased by 24%, reflecting growing preference for minimally invasive diagnostics. Device-related infection rates remained below 1.8%, supporting safety improvements.

6F: 6F devices dominate the market with 31% share, used in approximately 2.8 million procedures annually. These devices are widely applied in interventional cardiology procedures, accounting for 56% of their usage. Deployment efficiency exceeds 96%, with hemostasis achieved within 4 minutes in 82% of cases. The adoption rate increased by 23% between 2021 and 2024. Additionally, complication rates decreased by 18% due to improved device design and material composition. Same-day discharge was achieved in 72% of procedures using 6F devices. The use of advanced polymer-based materials increased durability by 27%. Training adoption among clinicians improved by 35%, enhancing procedural success rates. Device-related reintervention rates dropped to 2.2%, improving clinical outcomes.

7F: 7F devices hold 19% of the market, primarily used in complex interventional procedures. Approximately 1.6 million procedures utilized 7F devices in 2024. These devices offer enhanced structural stability, with deployment success rates of 94%. Their usage increased by 14% over three years, driven by rising demand for advanced cardiovascular interventions. Hospitals reported a 16% reduction in vascular complications when using 7F devices compared to manual compression. Hemostasis was achieved within 7 minutes in 74% of cases. Adoption in high-risk patient groups increased by 19%, supporting specialized procedures. Imaging-guided deployment improved accuracy by 28%. Device durability improvements reduced failure rates to 3.1%, enhancing reliability in complex cases.

8F: 8F devices represent 14% of the market, used in high-risk and large-diameter interventions. Around 1.2 million procedures utilized 8F devices globally in 2024. These devices provide superior closure strength, with success rates of 93%. Adoption increased by 11% due to advancements in device design. However, complication rates remain slightly higher at 4.2%, requiring skilled operators for optimal outcomes. Hemostasis time averaged 8 minutes in 69% of procedures. Usage in structural heart interventions increased by 22%, reflecting growing clinical demand. Advanced sealing mechanisms improved closure efficiency by 26%. Training requirements for 8F device handling increased by 31%, emphasizing the need for skilled professionals.

Others: Other device types account for 10% of the market, including specialized and hybrid closure systems. These devices are used in approximately 850,000 procedures annually. Adoption increased by 9% due to niche applications in peripheral interventions. Success rates vary between 90% and 95%, depending on device type and procedure complexity. Innovation in this segment increased by 27% between 2022 and 2025. Hybrid closure systems improved procedural flexibility by 34%. Usage in peripheral vascular interventions increased by 21%. Device customization options expanded by 18%, supporting patient-specific treatment approaches. Complication rates decreased by 14%, improving safety in specialized procedures.

By Application

Hospital: Hospitals dominate the market with 74% share, performing over 10 million procedures annually involving closure devices. Adoption rates reached 71% in tertiary care hospitals, with complication reduction of 24%. Hospitals reported a 39% improvement in patient turnover due to faster recovery times. Advanced imaging integration increased by 33% in hospital settings, enhancing procedural accuracy. Same-day discharge rates improved by 36%, reducing inpatient load. Robotic-assisted procedures increased by 22%, supporting precision-based interventions. Training programs expanded by 41%, improving clinician expertise. Device utilization in emergency procedures increased by 18%, reflecting broader application in critical care.

Clinic: Clinics account for 26% of the market, performing approximately 3.5 million procedures annually. Adoption increased by 22% due to the rise in outpatient care. Clinics reported a 28% reduction in recovery time and a 19% decrease in complications using closure devices. The use of portable closure systems increased by 31%, supporting clinic-based procedures. Same-day patient discharge was achieved in 81% of clinic procedures. Device adoption in ambulatory surgical centers increased by 27%. Training availability improved by 33%, enhancing procedural efficiency. Patient satisfaction rates increased by 29%, driven by faster recovery and reduced hospital visits.

Femoral Artery Closure Devices Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America holds 42% market share, with over 6 million procedures annually. The United States contributes 78% of the regional market, with Canada accounting for 12% and Mexico 10%. Adoption rates exceed 72% in hospitals, with complication rates reduced by 23%. Technological advancements increased device efficiency by 34%, and outpatient procedures grew by 29%. Training programs expanded by 41%, supporting clinician expertise. Over 1,800 hospitals utilize advanced closure devices, and device innovation increased by 38% between 2022 and 2025. Additionally, same-day discharge rates improved by 36%, reducing inpatient burden significantly. The use of bioabsorbable closure devices increased by 44% across leading healthcare facilities. Clinical success rates reached 97% in tertiary care centers, while readmission rates dropped by 18%. Robotic-assisted catheterization procedures increased by 22%, supporting precision-based device deployment. Patient satisfaction scores improved by 31% due to reduced recovery time and lower complication risks.

Europe

Europe accounts for 29% market share, with over 4 million procedures annually. Germany, France, and the UK contribute 61% of regional demand. Adoption rates reached 64% in hospitals, with complication reduction of 21%. Government healthcare investments increased by 18%, supporting advanced device adoption. Outpatient procedures grew by 26%, and device innovation increased by 32%. Training programs expanded by 35%, improving procedural success rates. The use of suture-mediated closure devices increased by 37% in major European hospitals. Same-day ambulation rates improved by 28%, enhancing patient recovery efficiency. Advanced imaging integration grew by 33%, improving procedural accuracy. Public healthcare systems supported 69% of closure device procedures, ensuring widespread accessibility. Clinical trial activity increased by 24%, strengthening product validation and adoption. Device-related infection rates dropped by 16%, improving overall patient safety outcomes.

Asia-Pacific

Asia-Pacific holds 21% market share, with over 3 million procedures annually. China, Japan, and India contribute 67% of regional demand. Adoption rates increased to 58%, with a 27% rise in catheterization labs. Government investments grew by 24%, supporting infrastructure development. Device innovation increased by 29%, and outpatient procedures rose by 31%. Complication rates decreased by 17%, improving patient outcomes. The number of trained interventional cardiologists increased by 34%, supporting procedural growth. Bioabsorbable device adoption rose by 41% across major healthcare systems. Same-day discharge rates improved by 26%, reducing hospital congestion. Rural healthcare expansion contributed to a 19% increase in device accessibility. Clinical success rates improved to 95% in urban hospitals, while training initiatives increased by 38%, enhancing procedural efficiency. Device manufacturing within the region increased by 23%, supporting supply chain stability.

Middle East & Africa

The Middle East & Africa region accounts for 8% market share, with over 1.2 million procedures annually. Adoption rates reached 49%, with a 19% increase in healthcare investments. Device usage increased by 23%, and outpatient procedures grew by 21%. Training programs expanded by 28%, improving clinician expertise. Complication rates decreased by 15%, supporting market growth. The number of specialized cardiac centers increased by 32%, enhancing procedural capacity. Bioabsorbable device adoption rose by 27%, reflecting technological advancement. Same-day discharge rates improved by 18%, supporting efficient patient management. Government initiatives contributed to a 25% increase in healthcare infrastructure development. Clinical success rates reached 93% in advanced facilities, while device availability improved by 22% across urban regions. Partnerships with global manufacturers increased by 30%, supporting knowledge transfer and training programs.

List of Top Femoral Artery Closure Devices Companies

• Abbott Laboratories
• Terumo Corporation
• Cordis
• Teleflex Incorporated
• Morrris Innovative

Top Two Companies with Hightest Market Share

• Abbott Laboratories holds 21% market share with over 2.3 million devices deployed annually and a 96% success rate
• Terumo Corporation holds 15% market share with over 1.7 million devices used annually and a 95% success rate

Investment Analysis and Opportunities

Investment in the femoral artery closure devices market increased by 27% between 2022 and 2025, with over 180 new projects initiated globally. Venture capital funding accounted for 34% of total investments, while corporate funding contributed 46%. Research and development spending increased by 31%, focusing on bioabsorbable materials and automated deployment systems. Over 65% of investments targeted emerging markets, where procedure volumes increased by 22%. Additionally, partnerships between manufacturers and healthcare providers grew by 29%, enhancing product adoption.

The demand for outpatient procedures created investment opportunities, with 33% of funding directed toward portable and cost-effective devices. Manufacturing expansion increased by 25%, supporting global supply chains. Clinical trials increased by 41%, improving product validation and regulatory approvals. Innovation hubs contributed to 38% of new product developments, supporting market expansion and technological advancements.

New Product Development

New product development in the femoral artery closure devices market increased by 39% between 2023 and 2025. Over 120 new devices were introduced globally, with 52% featuring bioabsorbable materials. Deployment time improved by 28%, reducing procedure duration. Success rates increased to 97% in advanced devices, compared to 92% in earlier models.

Manufacturers focused on reducing complication rates, achieving a 21% improvement in patient outcomes. Automated deployment systems increased by 36%, enhancing precision. Integration with imaging technologies improved accuracy by 33%. Additionally, 47% of new devices are designed for outpatient procedures, supporting faster recovery. Material innovation increased durability by 19%, while reducing failure rates to 2.3%. Clinical adoption of new devices reached 58% within the first year of launch.

Five Recent Developments (2023-2025)

• In 2023, Abbott Laboratories launched a new closure device with 97% success rate and 18% faster deployment time
• In 2024, Terumo Corporation introduced a bioabsorbable device reducing complications by 22%
• In 2023, Teleflex Incorporated expanded manufacturing capacity by 26%, increasing supply output
• In 2025, Cordis developed an imaging-guided closure system improving accuracy by 34%
• In 2024, Morrris Innovative introduced a hybrid device reducing recovery time by 29%

Report Coverage of Femoral Artery Closure Devices Market

The report covers comprehensive analysis of the femoral artery closure devices market, including over 25 countries and 150 data points. It evaluates procedural volumes exceeding 14 million annually and analyzes adoption rates across hospitals and clinics. The report includes segmentation by device type and application, covering 5 major categories and 2 primary applications. Regional analysis spans 4 key regions with over 40 country-level insights. The report examines technological advancements, highlighting over 120 new product developments and 180 investment projects. It includes analysis of complication rates, success rates, and deployment efficiency, providing over 60 performance metrics. Competitive analysis covers 5 major companies and 20 emerging players, evaluating market share distribution and innovation trends. Additionally, the report provides insights into regulatory frameworks, clinical adoption patterns, and healthcare infrastructure developments, supporting strategic decision-making.